Study #2020-0227
A Phase 1 Study of NKX101, an Activating Chimeric Receptor - Natural Killer (ACR NK) Cell Therapy, in Subjects with Hematological Malignancies or Dysplasias
MD Anderson Study Status
Not Accepting
Treatment Agent
NKX101 - CAR NK cell therapy
Description
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Study phase:
Phase I
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.